THE NATURAL HISTORY OF ULCERATIVE COLITIS

doi:10.1016/S0140-6736(57)90667-0

The Lancet

Volume 269, Issue 6967, 9 March 1957, Pages 487-489

https://doi.org/10.1016/S0140-6736(57)90667-0 Get rights and content

First page preview

Click to open first page preview

View PDF

References (4)

G. Lumb et al.
Lancet
(1955)

There are more references available in the full text version of this article.

Cited by (8)

Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last
2022, Gastroenterology
Citation Excerpt :
However, whether immunosuppressants, biologics, or small-molecule drugs and their timing of initiation affect the long-term progressive course of IBD remains unclear, leading to the need for prospective “disease-modification” trials. Disease modification can be defined as any treatment or intervention that has a beneficial outcome on long-term disease progression,55 ie, IBD “natural history,” a term that was introduced for UC and CD in 1957 and 1965, respectively.56,57 Surgery and hospitalization rates have long been easily implementable surrogate markers to describe the natural history of IBD and the long-term effect of medical treatments,58–60 in both pediatric and elderly patients.61–67
Short- and long-term treatment targets in inflammatory bowel diseases (IBDs) evolved during the last decade, shifting from symptom control to endoscopic healing and patient-centered parameters. The STRIDE-II consensus placed these targets on a timeline from initiating treatment and introduced additional targets, normalization of serum and fecal biomarkers, restoration of quality of life, prevention of disability, and, in children, restoration of growth. Transmural healing in Crohn’s disease and histologic healing in ulcerative colitis currently serve as adjunct measures to gauge remission depth. However, whether early treatment according to a treat-to-target paradigm affects the natural course of IBD remains unclear, leading to the need for prospective disease-modification trials. The SPIRIT consensus defined the targets for these trials to assess the long-term impact of early treatment on quality of life, disability, disease complications, risk of neoplastic lesions, and mortality. As further data emerge about the risk-benefit balance of aiming toward deeper healing, the targets in treating IBDs may continue to shift.
Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts
2012, Inflammatory Bowel Diseases
The natural history of adult crohn's disease in population-based cohorts
2010, American Journal of Gastroenterology
The risk of colorectal cancer in ulcerative colitis: A meta-analysis
2001, Gut
Has smoking changed the epidemiology of ulcerative colitis?
1992, Scandinavian Journal of Gastroenterology
Colitis in the Elderly: A Reappraisal
1981, The American Journal of Gastroenterology

View all citing articles on Scopus

^☆: * Read at the International Congress of Gastroenterology (5th meeting of l'Association des Societés Européennes et Méditeranéennes de Gastroenterologie) held in London, July, 1956.

View full text

ORIGINAL ARTICLESTHE NATURAL HISTORY OF ULCERATIVE COLITIS☆

First page preview

Lancet

ORIGINAL ARTICLES
THE NATURAL HISTORY OF ULCERATIVE COLITIS☆